Kayothera
  • Science
  • Team
  • Investors
  • News
  • Contact
Select Page
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

Sep 18, 2023 | News, Press Release

 Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies  Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —...
Washington state backs AI-driven cancer diagnostics and other startup projects

Washington state backs AI-driven cancer diagnostics and other startup projects

Aug 11, 2023 | News

Washington state backs AI-driven cancer diagnostics and other startup projects – GeekWire
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million

Jul 19, 2023 | News, Press Release

New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding  Additional funding will support advancement of KayoThera’s development programs in diabetes and oncology...
Washington state backs AI-driven cancer diagnostics and other startup projects

Kayothera Announces Expansion to Type 2 Diabetes with New Pipeline Addition

May 18, 2023 | News

Kayothera, an early-stage therapeutics company developing 1st-in-class, orally-available antagonists of the retinoid pathway, announces that it is advancing a program to treat and reverse cardiometabolic diseases, with a focus on Type 2 Diabetes. The clinical use of...
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

Kayothera, Inc. and Columbia University Announce Publication in Nature Communications Detailing Novel Therapeutic Strategy for Type 2 Diabetes

Feb 2, 2023 | News, Press Release

Seattle, WA — February 02, 2023,  A paper published today in the peer-reviewed journal Nature Communications, co-authored by researchers from Columbia University, Kayothera, Inc., and Princeton University, describes a new therapeutic strategy for treatment of type 2...
Washington state backs AI-driven cancer diagnostics and other startup projects

Kayothera Founder Presented with Princeton University’s Tiger Entrepreneur Award

Oct 18, 2022 | News

Princeton Entrepreneurship Council is pleased to announce the winners of the 2022 Tiger Entrepreneur Award. For the last six years, the Tiger Entrepreneur Award has been given to celebrate the value of entrepreneurship across the Princeton community and to emphasize...
« Older Entries
Next Entries »

Categories

  • Events (2)
  • News (21)
  • Press Release (7)
  • Contact
    © 2024 KAYOTHERA® — All Rights Reserved